“…Recently, we have reported on efforts to increase the volatility of homoleptic Cu(II) b-diketonate complexes by the incorporation of trialkylsilyl substituents in the supporting ancillary ligands [8][9][10][11]. In particular, the complex Cu(tmshd) 2 (where tmshd is the anion of 2,2,6,6-tetramethyl-2-silaheptane-3,5-dione) sublimes at a significantly lower temperature than its carbon analogue, Cu(tmhd) 2 (where tmhd is the anion of 2,2,6,6-tetramethylheptane-3,5-dione) [9] and is a viable, nonfluorinated candidate for MOCVD [8]. Further, the silylated Cu(II) compounds generally show greater stability than the corresponding non-silylated complexes [9][10][11]; the larger differences between the sublimation and decomposition temperatures should allow for the ability to attenuate the properties of the complex to fit a specific MOCVD application.…”